Citigroup Inc Nkarta, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Nkarta, Inc. stock. As of the latest transaction made, Citigroup Inc holds 40,451 shares of NKTX stock, worth $95,059. This represents 0.0% of its overall portfolio holdings.

Number of Shares

40,451

Previous 52,634 23.15%

Holding current value

$95,059

Previous $311,000 41.48%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$4.52 - $8.0 $55,067 - $97,464	-12,183 Reduced 23.15%	40,451 $182,000
Q2 2024 Aug 12, 2024	BUY	$5.27 - $10.82 $17,143 - $35,197	3,253 Added 6.59%	52,634 $311,000
Q1 2024 May 10, 2024	BUY	$5.59 - $15.71 $251,857 - $707,814	45,055 Added 1041.49%	49,381 $533,000
Q4 2023 Feb 09, 2024	SELL	$1.31 - $6.6 $1,199 - $6,045	-916 Reduced 17.47%	4,326 $28,000
Q3 2023 Nov 09, 2023	SELL	$1.39 - $2.29 $7,874 - $12,972	-5,665 Reduced 51.94%	5,242 $7,000
Q2 2023 Aug 10, 2023	BUY	$2.19 - $5.17 $20,329 - $47,993	9,283 Added 571.61%	10,907 $23,000
Q1 2023 May 11, 2023	BUY	$3.37 - $6.3 $117 - $220	35 Added 2.2%	1,624 $5,000
Q4 2022 Feb 09, 2023	SELL	$5.14 - $14.35 $744,991 - $2.08 Million	-144,940 Reduced 98.92%	1,589 $9,000
Q3 2022 Nov 10, 2022	BUY	$12.27 - $18.39 $1.2 Million - $1.8 Million	98,085 Added 202.47%	146,529 $1.93 Million
Q2 2022 Aug 10, 2022	BUY	$7.77 - $19.44 $363,332 - $909,033	46,761 Added 2778.43%	48,444 $597,000
Q1 2022 May 12, 2022	SELL	$8.66 - $14.99 $49,665 - $85,967	-5,735 Reduced 77.31%	1,683 $19,000
Q4 2021 Feb 10, 2022	SELL	$12.79 - $26.88 $354,206 - $744,414	-27,694 Reduced 78.87%	7,418 $114,000
Q3 2021 Nov 10, 2021	BUY	$26.67 - $38.76 $936,437 - $1.36 Million	35,112 New	35,112 $976,000

Others Institutions Holding NKTX

# of Institutions

129

Shares Held

66.5M

Call Options Held

173K

Put Options Held

20K

View Full List

About Nkarta, Inc.

Ticker NKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,656,800
Market Cap $114M
Description
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the sur...

More about NKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account